A long-acting octreotide analog formed by conjugation with a peptide linker modified with two fatty acids

What Was Tested

Researchers studied Octreotide and Somatostatin in this randomized controlled trial publication.

To address this limitation, the researchers developed TE-8214, a depot-free octreotide analog conjugated to a soluble, dual-fatty-acid albumin-binding module designed to enable prolonged systemic exposure while maintaining a fully aqueous formulation suitable for subcutaneous administration through a fine 30-gauge needle.

Who Took Part

By PubMed's age tags, the people studied were young adults and adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Octreotide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Octreotide.

The comparison arm used a placebo, so changes seen with Octreotide could be set against what happens without it.

TE-8214's binding to human serum albumin (HSA) and somatostatin receptor 2 (SSTR2), and its receptor-mediated functional activity, were characterized in vitro and compared with octreotide.

What Was Measured

PubMed files the paper under topics including Dogs, Rats, Fatty Acids, Insulin-Like Growth Factor I, Octreotide and Receptors, Somatostatin.

The authors tagged it with the keywords IGF-1, acromegaly, albumin binding, neuroendocrine tumors and somatostatin analog.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Octreotide and Somatostatin.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2026 (Frontiers in endocrinology), a journal based in Switzerland.

More context: the Octreotide compound page and the Somatostatin compound page, all human trials.